Adjuvant combination formulations

Details Adjuvant combination formulations Adjuvant combination formulations

2000-05-12

2009-11-03

Le, Emily M. (Department: 1648)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

Reexamination Certificate

active

07611721

ABSTRACT:
The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.

REFERENCES:
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4912094 (1990-03-01), Myers et al.
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5057540 (1991-10-01), Kensil
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5078996 (1992-01-01), Conlon, III et al.
patent: 5223254 (1993-06-01), Paradiso et al.
patent: 5229496 (1993-07-01), Deeley et al.
patent: 5571515 (1996-11-01), Scott et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5603958 (1997-02-01), Morein et al.
patent: 5679356 (1997-10-01), Bonnem et al.
patent: 5723127 (1998-03-01), Scott et al.
patent: 5723130 (1998-03-01), Hancock et al.
patent: 5736361 (1998-04-01), Carbonetti et al.
patent: 5762943 (1998-06-01), Dolovich et al.
patent: 5776468 (1998-07-01), Hauser et al.
patent: 5830877 (1998-11-01), Carson et al.
patent: 5861243 (1999-01-01), Dietrich et al.
patent: 5932216 (1999-08-01), Celeste et al.
patent: 5939074 (1999-08-01), Berzofsky
patent: 5955087 (1999-09-01), Whittle et al.
patent: 5976539 (1999-11-01), Scott et al.
patent: 5980911 (1999-11-01), Corner et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 6024965 (2000-02-01), van Baalen et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6071893 (2000-06-01), Graham et al.
patent: 6096313 (2000-08-01), Jager et al.
patent: 6113918 (2000-09-01), Johnson et al.
patent: 6350456 (2002-02-01), Reed et al.
patent: 6488936 (2002-12-01), Mishkin et al.
patent: 6514503 (2003-02-01), Gizurarson et al.
patent: 6613337 (2003-09-01), Reed et al.
patent: 6797276 (2004-09-01), Glenn et al.
patent: 6929794 (2005-08-01), Mills et al.
patent: 671947 (2000-03-01), None
patent: WO 90/05147 (1990-05-01), None
patent: WO 91/16819 (1991-11-01), None
patent: WO 95/29700 (1995-11-01), None
patent: WO 96/10423 (1996-04-01), None
patent: WO 96/11019 (1996-04-01), None
patent: WO 97/28273 (1997-08-01), None
patent: WO 98/17799 (1998-04-01), None
patent: WO 98/20734 (1998-05-01), None
patent: WO 98/50399 (1998-11-01), None
patent: WO 98/56415 (1998-12-01), None
patent: WO 98/57659 (1998-12-01), None
patent: WO 9857659 (1998-12-01), None
patent: WO 99/02132 (1999-01-01), None
patent: WO 99/12565 (1999-03-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/40937 (1999-08-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 00/60084 (2000-10-01), None
patent: WO 00/69456 (2000-11-01), None
Result No. 1 of RAG Sequence Result Summary.
Ulrich et al. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In M.F. Powell and M.J. Newman (ed.), Vaccine Design. Plenum Press, New York, NY, p. 495-524.
Disis et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide based vaccines. Blood, 1996; vol. 88, No. 1: 202-210.
Bartlett et al. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. AIDS, 1998, vol. 12, No. 11, 1291-1300.
Finkelman, F.D. and Holmes, J., Ann Rev Immunol 8:303-333 (1990).
Snapper, C.M. et al., J Exp Med 175:1367-1371 (1992).
Kobayashi, M., et al., J Exp Med 170:827-845 (1989).
Alderson, M.R. et al., J Exp Med 178:669-674 (1993).
Snapper, C.M. et al., J Immunol 154:5842-5850 (1995).
Charbit, A. et al., Vaccine 11:1221-1228 (1993).
Natuk, R.J. et al., AIDS Res Hum Retroviruses 9:395-404 (1993).
Johnson, R.P. et al., J Virol 68:3145-3153 (1994).
Fuller, D.H. et al., AIDS Res Hum Retroviruses 10:1433-1441 (1994).
Berzofsky, J.A. et al., J Clin Invest 88:876-884 (1991).
Palker, T.J. et al., J Immunol 142:3612-3619 (1989).
Hart, M.K. et al., J Immunol 145:2677-2685 (1990).
Haynes, B.F. et al., J Immunol 151:1646-1653 (1993).
Hart, M.K. et al., Proc Natl Acad Sci USA 88:9448-9452 (1991).
Bartlett, J.A. et al., AIDS 12:1291-1300 (1998).
Haynes, B.F. et al., AIDS Res Hum Retroviruses 11:211-221 (1998).
Staats, H.F. et al., J Immunol 157:462-472 (1996).
Porgador, A. et al., J Immunol 158:834-841 (1997).
Allen, T.M. et al., J Immunol 160:6062-6071 (1998).
Miller, M.D. et al., J Immunol 147:320-329 (1991).
Egan, M.A. et al., J Virol 73:5466-5472 (1999).
Kuroda, M.J. et al., J Exp Med 187:1373-1381 (1998).
Shijns, Virgil EJC; Immunological concepts of vaccine adjuvant activity; Commentary; Current Opinion in Immunology; 2000, 12:456-463.
Abbas, Abul K., et al.; Cellular And Molecular Immunology; Cytokines; Library of Congress Cataloging-in-Publication Data; 1994; Chapter 12; pp. 240-260.
Vaslin, B. et al., Vaccine 12:1132-1140 (1994).
Mosmann, T.R. et al., J Immunol 136:2348-2357 (1986).
Ahlers, J.D. et al., J Immunol 158:3947-3958 (1997).
Scharton-Kersten, T. et al., J Immunol 154:5320-5330 (1995).
Ghalib, H.W. et al., J Immunol 154:4623-4629 (1995).
Murray, H.W. and Hariprashad, J., J Exp Med 181:387-391(1995).
USPTO Final Office Action, Mailed Mar. 17, 2008, Hagen, Michael, U.S. Appl. No. 10/416,262, filed May 8, 2003, Adjuvant Combination Formulations.
USPTO Final Office Action, Mailed Oct. 17, 2008, Hagen, Michael, U.S. Appl. No. 11/544,056, filed Oct. 6, 2006, Adjuvant Combination Formulations.
Silla, S. et al., “Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL,” 1999, European Cytokine Network, vol. 10(2), pp. 181-189.
Hancock, G. E. et al., “QS-21 Synergizes with Recombinant Interleukin-12 to Create a Potent Adjuvant Formulation for the Fusion Protein of Respiratory Syncytial Virus,” 2000, Viral Immunology, vol. 13(4), pp. 503-509.
Weinberg, A. et al., “Recombinant Interleukin 2 As An Adjuvant for Vaccine-induced Protection,” Jan. 1, 1988, Journal of Immunology, vol. 140(1), pp. 294-299.
Datta, S. K. et al, “Antigen-immunostimulatory oligo-nucleotide conjugates: mechanisms and applications,” Jun. 2004, Immunological Reviews, vol. 199, pp. 217-226, Abstract Only.
Schoenhaut, D. S. et al., “Cloning and Expression of Murine IL-12,” Jun. 1, 1992, Journal of Immunology, vol. 148(11), pp. 3433-3440.
Singh, M. et al., “Advances in vaccine adjuvants,” Nov. 1999, Nature Biotechnology, vol. 17(11), pp. 1075-1081.
Vaslin, B. et al., “Induction of humoral and cellular immunity to simian immunodeficiency virus: what are the requirements for protection?” 1994, Vaccine, vol. 12, pp. 1132-1140.

Affiliated with

Also associated with

Rating

Adjuvant combination formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adjuvant combination formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adjuvant combination formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4119384